| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCND1 |
| Uniprot No | P24385 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-295aa |
| 氨基酸序列 | MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSMVAAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI |
| 预测分子量 | 81.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCND1重组蛋白的假设性参考文献示例(仅供格式参考，非真实文献)：
1. **标题**：*Expression and Purification of Recombinant Human CCND1 for Functional Studies*
**作者**：Smith A, et al.
**摘要**：本研究描述了一种在大肠杆菌中高效表达和纯化重组人CCND1蛋白的方法，通过亲和层析和尺寸排阻色谱获得高纯度蛋白，并验证其与CDK4的体外结合活性。
2. **标题**：*Structural Insights into CCND1-CDK6 Complex Formation Using Recombinant Proteins*
**作者**：Lee J, et al.
**摘要**：利用重组表达的CCND1和CDK6蛋白，通过X射线晶体学解析了二者复合物的三维结构，揭示了关键结合界面，为靶向抑制剂的开发提供依据。
3. **标题**：*Role of Recombinant CCND1 in Cell Cycle Dysregulation in Breast Cancer Models*
**作者**：Wang Y, et al.
**摘要**：通过体外过表达重组CCND1蛋白，研究证实其在乳腺癌细胞中加速G1/S期转换，并促进肿瘤生长，提示其作为治疗靶点的潜力。
4. **标题**：*Optimizing Mammalian Cell Systems for CCND1 Recombinant Production*
**作者**：Garcia R, et al.
**摘要**：比较昆虫细胞和HEK293细胞表达系统对重组CCND1蛋白翻译后修饰的影响，发现哺乳动物系统更接近天然构象，适用于功能研究。
---
**注意**：以上为模拟示例，实际引用时需通过PubMed、Web of Science等平台检索真实文献。如需具体文献推荐，请提供更多研究背景或关键词。
**Background of CCND1 Recombinant Protein**
CCND1 (Cyclin D1), encoded by the *CCND1* gene on chromosome 11q13. is a regulatory protein critical for cell cycle progression. It functions as a key regulator of the G1-to-S phase transition by forming complexes with cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6. These complexes phosphorylate retinoblastoma (Rb) protein, releasing transcription factors that drive DNA replication and cell division. Dysregulation of CCND1 is implicated in various cancers, as overexpression leads to uncontrolled proliferation, genomic instability, and tumorigenesis.
Recombinant CCND1 protein is engineered using biotechnological methods, often expressed in *E. coli* or mammalian systems, to produce high-purity, functional protein for research. It typically retains structural features, such as the cyclin box domain, necessary for binding CDKs and Rb. Researchers utilize recombinant CCND1 to study cell cycle mechanisms, protein interactions, and oncogenic mutations. It also serves as a tool for screening CDK inhibitors, which are therapeutic agents in cancers with CCND1 amplification (e.g., breast cancer, mantle cell lymphoma).
In drug development, CCND1 recombinant protein aids in validating targets like CDK4/6 inhibitors (e.g., palbociclib) and understanding resistance mechanisms. Its role extends to diagnostic applications, as CCND1 overexpression correlates with poor prognosis in certain malignancies. By enabling precise biochemical and cellular assays, recombinant CCND1 remains vital for unraveling cancer biology and advancing targeted therapies.
×
